Technetium 99mTc-MIBI scintigraphy in patients with multiple myeloma: A sensitive marker of the biological disease activity;Scintigrafie pomocí 99mTc-MIBI v diagnostice mnohočetného myelomu: Senzitivní ukazatel biologické aktivity choroby

Klinicka Onkologie

Volumn 17, Issue 1, 2004, Pages 13-17

  Myslivecek M ^a   Bacovsky J ^a   Kaminek M ^a   Koranda, P ^a   Vytrasova M ^a   Husak V ^a   Scudla V ^a   Nekula, J ^a  

^a UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

Author keywords

99mTc MIBI; Assessing myeloma activity; Multiple myeloma; Pattern of uptake; Whole body scintigraphy

Indexed keywords

METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M;

ARTICLE; DIAGNOSTIC ACCURACY; DISEASE ACTIVITY; HUMAN; MAJOR CLINICAL STUDY; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; RADIOISOTOPE DISTRIBUTION; TISSUE DISTRIBUTION; TUMOR LOCALIZATION; WHOLE BODY SCINTISCANNING;

EID: 3042599695     PISSN: 0862495X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. 99mTc SPECT [abstract]. J Nucl Med 1987; 28: 562P.
2. Khalkhali I, Mena I, Diggles L. Review of imaging techniques for the diagnosis of breast cancer: a new role of prone scintimammography using technetium-99m-sestamibi. Eur J Nucl Med 1994; 21: 357-62.
3. 99mTc-MIBI scintimammography in suspected breast cancer. J Nucl Med 1999; 40: 296-301.
4. Kao CH, Wang SJ, Lin WY, et al. Differentiation of single-solid lesions in the lungs by means of single photon emission tomography with technetium-99m-methoxyisobutylisonitrile. Eur J Nucl Med 1993; 20: 249-54.
5. Bom HS, Kim YC, Song HC, et al. Technetium-99m-MIBI uptake in small cell lung cancer. J Nucl Med 1998; 39: 91-94.
6. Soler C, Beauchesne P, Maatougui K, et al. Technetium-99m sestamibi brain single-photon emission tomography for detection of recurrent gliomas after radiation therapy. Eur J Nucl Med 1998; 25: 1649-57.
7. Foldes I, Levay A, Stotz G. Comparative scanning of thyroid nodules with technetium-99m-methoxyisobutylisonitrile. Eur J Nucl Med 1993; 20: 330-33.
8. Soderlund V, Jonsson C, Bauer HCF, et al. Comparison of technetium-99m-MIBI and technetium-99m-tetrofosmin uptake by musculoskeletal sarcomas. J Nucl Med 1997; 38: 682-86.
9. Ziegels P, Nocaudie M, Huglo D, et al. Comparison of technetium-99m methoxyisobutylisonitrile and gallium-67 citrate scanning in the assessment of lymphomas. Eur J Nucl Med 1995; 22: 126-31.
10. Tailefer R, Boucher Y, Potvin C, Lambert R. Detection and localization of parathyroid adenomas in patients with hyperparathyreoidism using a single radionuclide imaging procedure with techentium-99m-sestamibi (double-phase study). J Nucl Med 1992; 33: 1801-07.
11. Durie BGM, Waxman A, Jochelson M, et al. Technetium-99m-MIBI scanning in multiple myeloma (MM) [abstract]. Proc Am Soc Clin Oncol 1994; 13: 411.
12. Unlu M, Haznedar R, Atavci S, et al. Detection of bone lesion in multiple myeloma using Tc-99m MIBI scintigraphy [abstract]. Eur J Nucl Med 1995; 22 [Suppl]: 739.
13. Tirovola EB, Biassoni L, Britton KE, et al. The use of 99m-Tc-MIBI scanning in multiple myeloma. Br J Cancer 1996; 74: 1815-20.
14. Adams BK, Fataar A, Nizami MA. Technetium-99m-sestamibi uptake in myeloma. J Nucl Med 1996; 37: 1001-02.
15. El-Shirbiny AM, Yeung H, Imbriaco M, et al. Technetium-99m-MIBI versus fluorine-18-FDG in diffuse multiple myeloma. J Nucl Med 1997; 38:1208-10.
16. Catalano L, Pace L, Califano C, et al. Detection of focal myeloma lesions by technetium-99m-sestaMIBI scintigraphy. Haematologica 1999; 84: 119-24.
17. 99mTc-MIBI in patients with multiple myeloma. Eur J Nucl Med 2001; 28: 214-20.
18. Alexandrakis MG, Kyriakou DS, Passam F, et al. Value of Tc-99m sestamibi scintigraphy in the detection of bone lesions in multiple myeloma: comparison with Tc-99m methylene diphosphonate. Ann Hematol 2001; 80: 349-53.
19. Balleari E, Villa G, Garre S, et al. Technetium-99m-sestamibi scintigraphy in multiple myeloma and related gammopathies: a useful tool for the indentification and follow-up of myeloma bone disease. Haematologica 2001; 86: 78-84.
20. Ščudla V, Bačovský J. Prognostické faktory u mnohočetného myelomu. In: Adam Z a spol.: Mnohočetný myelom a další monoklonální gamapatie, edit. Masarykova univerzita Brno, 1999, 157-73.
21. Ščudla V, Ordeltová M. Klinický a biologický význam vyšetřování proliferačních charakteristik plazmocytů u mnohočetného myelomu. In: Adam Z a spol. Mnohočetný myelom a další monoklonálni gamapatie. edit. Masarykova univerzita Brno, 1999, 175-84.
22. Ščudla V, Ordeltová M, Bačovský J, et al. Conception of the inverse relationship between the proliferation and apoptosis activity in plasma cell compartments of patients with monoclonal gammopathy of undetermined significance and multiple myeloma. Hematol J 2003; 4: (in press).
23. Pace L, Catalano L, Del Vecchio S, et al. Predictive value of technetium-99m sestamibi in patients with multiple myeloma and potential role in the follow-up. Eur J Nucl Med 2001; 28: 304-12.
24. Pace L, Catalano L, Pinto AM, et al. Different patterns of technetium-99m sestamibi uptake in multiple myeloma. Eur J Nucl Med 1998; 25: 714-20.
25. Alexandrakis MG, Kyriakou DS, Passam FH, et al. Correlation between the uptake of Tc-99m-sestaMIBI and prognostic factors in patients with multiple myeloma. Clin Lab Haematol 2002; 24: 155-59
26. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975; 36: 842-54.
27. Svaldi M, Tappa C, Gebert U, et al. Technetium-99m-sestamibi scintigraphy: an alternative approach for diagnosis and follow-up of active myeloma lesions after high-dose chemotherapy and autologous stem cell transplantation. Ann Hematol 2001; 80: 393-97.
28. Wakasugi S, Noguti A, Katuda T, et al. Potential of 99mTc-MIBI for detecting bone marrow metastases. J Nucl Med 2002; 43: 596-602.